Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare

C.A. Janssen*, M.A.H. Oude Voshaar, P.M. ten Klooster, H.E. Vonkeman, M.A.F.J. van de Laar

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
27 Downloads (Pure)

Abstract

Lowering serum urate levels below the threshold for crystal formation with urate-lowering therapy (ULT) has been associated with a lower risk for gout flare reoccurrences. However, gout patients on ULT still commonly suffer from recurring gout flares. The purpose of this study was to explore prognostic factors associated with gout flare recurrence within the first 3 months, in gout patients starting ULT during an acute gout flare. Post-hoc analysis of trial data on acute gout patients randomized to either gout flare standard of care or anakinra treatment were used, including baseline demographic, laboratory, clinical, and patient-reported variables, as well as 3-month follow-up data on gout flare recurrences. Only patients starting ULT at baseline were included. Using variable selection based on clinical relevance, univariate, and multivariate binary logistic regression analyses were done to examine predictors of gout flare reoccurrence. A total of 75 patients were included in this study, of which 36 (48%) experienced a gout flare ≤ 3 months post baseline. The multivariate regression analysis revealed that CRP levels > 30 mg/L (OR 9.47) and lack of prophylaxis when starting ULT (OR 11.56) were independently associated with gout flare recurrence. Similar results were found for the univariate regression analyses. Our results show that CRP levels > 30 mg/L and lack of prophylaxis when starting ULT were prognostic factors for early gout flare reoccurrence in patients starting ULT during an acute gout flare. Key Points: • Gout flare recurrences were common within the first 3 months after starting urate-lowering therapy in gout patients. • Intake of prophylaxis when starting ULT had a strong protective effect on gout flare recurrences. • C-reactive protein level > 30 mg/L was an additional prognostic factor for early (≤ 3 months) gout flare reoccurrence in patients starting ULT during an acute gout flare.

Original languageEnglish
Pages (from-to)2233-2239
Number of pages7
JournalClinical rheumatology
Volume38
Issue number8
Early online date27 Apr 2019
DOIs
Publication statusPublished - 1 Aug 2019

Keywords

  • UT-Hybrid-D
  • Gout
  • Prognostic factors
  • Urate-lowering therapy
  • Flares

Fingerprint Dive into the research topics of 'Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare'. Together they form a unique fingerprint.

  • Cite this